Earnings Feed
Start Free
Home/Filings/4/0001209191-14-050684
4//SEC Filing

IDENIX PHARMACEUTICALS INC 4

Accession 0001209191-14-050684

CIK 0001093649operating
View on SEC.govCompany Profile

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 5:42 PM ET

Size

25.5 KB

Accession

0001209191-14-050684

Insider Transaction Report

Form 4
Period: 2014-08-05
IDENIX PHARMACEUTICALS INCIDIX
Pollard-Knight Denise
Director
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $6.71Exp: 2018-06-02→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $8.85Exp: 2016-06-13→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $4.94Exp: 2023-06-05→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $7.33Exp: 2017-05-30→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $3.49Exp: 2019-06-01→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $4.57Exp: 2021-06-01→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $4.09Exp: 2020-06-02→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $9.03Exp: 2022-06-06→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05−20,000→ 0 total
    Exercise: $6.88Exp: 2024-06-04→ Comon Stock (20,000 underlying)
Footnotes (9)
  • [F1]These options, which vested in 12 equal monthly installments beginning on July 14, 2006, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. (the "Merger Agreement") in exchange for a cash payment of $15.65 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F2]These options, which vested in 12 equal monthly installments beginning on June 30, 2007, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.17 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F3]These options, which vested in 12 equal monthly installments beginning on July 3, 2008, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.79 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F4]These options, which vested in 12 equal monthly installments beginning on July 2, 2009, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $21.01 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F5]These options, which vested in 12 equal monthly installments beginning on July 3, 2010, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $20.41 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F6]These options, which vested in 12 equal monthly installments beginning on July 2, 2011, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.93 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F7]These options, which vested in 12 equal monthly installments beginning on July 7, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $15.47 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F8]These options, which vested in 12 equal monthly installments beginning on July 6, 2013, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.56 per share, representing the difference between the exercise price of the options and $24.50 per share.
  • [F9]These options, which vested in 12 equal monthly installments beginning on July 5, 2014, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.62 per share, representing the difference between the exercise price of the options and $24.50 per share.

Documents

1 file

Issuer

IDENIX PHARMACEUTICALS INC

CIK 0001093649

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001093649

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:42 PM ET
Size
25.5 KB
View on SEC.gov